Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • US debt crisis: Joe Biden gets the deal done but at a cost
    • White House reaches deal with Republicans to avert US debt default
    • Recep Tayyip Erdoğan extends rule into third decade with Turkish election victory
    • Republican leaders try to quell debt deal revolt as US counts down to default
    • China’s first passenger jet completes maiden commercial flight
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Canada’s big banks log 13-fold rise in loan loss provisions
      • UK mid-market dining chains fight for survival after Covid and cost of living woes
      • Sky to cut hundreds of jobs in shift from satellite TV
      • Mike Lynch uses $50mn in Darktrace shares to secure US bail
      • Peter Orszag: the ‘scholar-banker’ named to restore Lazard’s fortunes
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • AI boom drives gains for chip stocks
      • Après debt ceiling deal, le T-bill déluge
      • India’s biggest alternative asset manager bets on private credit
      • Weddings and divorce: the scourge of investment returns
      • Is COP28 destined to be a flop?
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Buffett’s intriguing bet on Japan
      • What we get wrong about ageing and work
      • Now the UK is finally tackling ‘Londongrad’, it’s time the US upped its game
      • Citizens’ juries can help fix democracy
      • A stylist, yes, but Martin Amis was also right on the money
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’
      • Germany’s tangled relationship with Russia
      • Economist Daniel Chandler: ‘Shareholders have all the power. It doesn’t have to be that way.’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Yes, Suella Braverman should go, but not for the reason you think
      • GCHQ’s Jeremy Fleming: ‘Xi doesn’t want to see Putin humiliated’
      • The UK’s best bakeries: the readers’ picks
      • From Bowie to Jagger, the photos that created legends
      • We need to talk about picnics
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Jamie Smyth

    US Pharmaceutical Correspondent

    Jamie Smyth is the US pharmaceutical correspondent of the Financial Times. He is based in the New York bureau and covers the pharma and biotech sectors, drug discovery and healthcare issues such as the opioids crisis. He was previously Australia correspondent and Ireland correspondent.

    Before joining the FT Jamie worked as European correspondent for The Irish Times. He has a master’s degree in journalism from Dublin City University and a bachelor’s degree in history from Trinity College Dublin.

    Email Jamie Smyth @JamieSmythF  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Saturday, 27 May, 2023
      Illumina Inc
      Illumina accused by Brussels of ‘delay tactics’ on Grail divestiture

      World’s biggest gene sequencing company rejects EU’s fast- track application

    • Thursday, 25 May, 2023
      Illumina Inc
      Illumina chair ousted in proxy battle with Carl Icahn

      Vote to remove John Thompson is the culmination of one of the largest shareholder activism campaigns in years

    • Wednesday, 24 May, 2023
      Abbott Laboratories
      Infant formula producers probed by FTC over bids for contracts

      Inquiry by US regulator focuses on whether manufacturers colluded in relation to programme for low-income families

    • Wednesday, 24 May, 2023
      InterviewIllumina Inc
      Illumina can survive loss of chair and CEO, says board director

      Gene sequencing company heads for pivotal vote in battle with activist investor Carl Icahn

    • Wednesday, 17 May, 2023
      Mergers & Acquisitions
      M&A crackdown a ‘disaster’ for pharma sector, Pfizer executive warns

      Development chief raises worry over innovation after FTC sues to block Amgen-Horizon deal

    • Wednesday, 17 May, 2023
      Amgen Inc
      Regeneron boss backs attempt to block $28bn Amgen acquisition

      Leonard Schleifer supportive of FTC’s lawsuit against takeover of Horizon Therapeutics

    • Wednesday, 17 May, 2023
      The Big Read
      Quick blood tests to spot cancer: will they help or harm patients?

      Investors are pouring billions into companies claiming they can analyse DNA to find the disease early. But some scientists question if they really work

    • Sunday, 14 May, 2023
      Novavax Inc
      Cash-strapped Novavax urges governments to honour Covid jab deals

      US biotech group is among coronavirus vaccine makers struggling with reduced demand post-pandemic

    • Wednesday, 10 May, 2023
      Illumina Inc
      Glass Lewis backs Carl Icahn’s push to oust Illumina’s chief and chair

      Proxy adviser says the two executives failed to take responsibility for destructive deal for Grail

    • Monday, 8 May, 2023
      Dementia
      Two Alzheimer’s drugs offer hope to patients after decades of waiting

      In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

    • Thursday, 4 May, 2023
      Johnson & Johnson Co Inc
      J&J consumer arm’s shares jump in biggest US IPO since 2021

      Kenvue valued at $41bn after carve-out from US healthcare group

    • Wednesday, 3 May, 2023
      Eli Lilly & Co
      Eli Lilly to seek US approval after Alzheimer’s drug trial success

      Clinical study results could boost patient access to new class of treatment

    • Tuesday, 2 May, 2023
      Pfizer Inc
      Pfizer to start selling stake in Advil maker Haleon within months, says CFO

      US drugmaker adjusts strategy of pursuing deals to replenish drug pipeline

    • Monday, 1 May, 2023
      Noubar Afeyan
      Moderna co-founder calls on US politicians and judges to stop questioning science

      Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases

    • Friday, 28 April, 2023
      Special ReportThe Americas’ Fastest Growing Companies
      Moderna tries to show it’s not a ‘one trick pony’

      Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects

    • Thursday, 27 April, 2023
      Eli Lilly & Co
      Eli Lilly to seek approval of obesity drug that could disrupt weight loss market

      US pharma group’s late-stage study has shown treatment can slash body weight by nearly a sixth

    • Thursday, 27 April, 2023
      Johnson & Johnson Co Inc
      Talcum powder cancer claims target J&J’s new consumer carve-out

      Executives had tried to shield Kenvue from most of the asbestos lawsuits already facing the group

    • Wednesday, 26 April, 2023
      Medical science
      US regulators approve first human pill derived from faecal matter

      FDA gives green light to C. difficile treatment in boost for microbiome drug developers

    • Friday, 21 April, 2023
      Roe vs Wade
      US Supreme Court pauses restrictions on abortion pill

      Decision halts limitations imposed by a Texas judge earlier this month

    • Wednesday, 19 April, 2023
      Reproductive rights
      US Supreme Court leaves abortion pill ruling on hold

      Justice Samuel Alito extends deadline for further action until Friday

    • Tuesday, 18 April, 2023
      Johnson & Johnson Co Inc
      Johnson & Johnson reports loss after taking $6.9bn charge over talc claims

      Healthcare group to ask judge to halt lawsuits over talcum powder linked to cancer under auspices of bankruptcy system

    • Tuesday, 18 April, 2023
      Biotech
      Chinese genetics company targets US despite political tensions

      MGI Tech insists it can succeed even though parts of its former parent BGI Group have been blacklisted

    • Sunday, 16 April, 2023
      Mergers & Acquisitions
      Merck buys Prometheus Biosciences for almost $11bn

      Pharmaceutical and biotech deals are rebounding after a dip last year

    • Friday, 14 April, 2023
      Reproductive rights
      US Supreme Court puts abortion pill restrictions on temporary hold

      Justice Samuel Alito’s decision gives high court until next week to consider further action in the closely watched case

    • Thursday, 13 April, 2023
      Reproductive rights
      Biden administration asks US Supreme Court to block abortion pill ruling

      Appeals court preserved access to tablets containing mifepristone while temporarily imposing restrictions on them

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In